Notice of GM

Renalytix PLC

03 April 2024

 

Renalytix plc

("Renalytix" or the "Company")

Notice of General Meeting

LONDON and SALT LAKE CITY, April 3, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimising clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that a General Meeting ("GM") will be held on 22 April 2024 at 3.00 p.m. (BST) at 6 Stratton Street Mayfair, London W1J 8LD.

A proxy statement (including the notice of GM) will be posted to shareholders who have not consented to receive electronic communications later today and is now available to view on the Company website:

 https://investors.renalytix.com/news-and-events/documents-and-presentations

Hard copies of the form of proxy for the General Meeting will only be available upon request and instead, voting can be done electronically using the link www.signalshares.com. Investors will need to log into their Signal Shares account or register if they have not previously done so. All details about how to vote can be found in the notice of GM.

To help with practical arrangements for the GM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at [e-mail].

For further information, please contact:

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: [phone]
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Shalin Bhamra
Walbrook PR Limited		Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]
CapComm Partners
Peter DeNardo		Tel: [phone] or [e-mail]

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

END